OPGENRA

This brand name is authorized in Estonia, Lithuania

Active ingredients

The drug OPGENRA contains one active pharmaceutical ingredient (API):

1 Eptotermin alfa
UNII IT063R5MY0 - EPTOTERMIN ALFA

Eptotermin alfa, the active substance, initiates bone formation through the induction of cellular differentiation in mesenchymal cells, which are recruited to the implant site from bone marrow, periosteum and muscle. Once bound at the cell surface, the active substance induces a cascade of cellular events leading to the formation of chondroblasts and osteoblasts, which play a key role in the bone formation process.

Read about Eptotermin alfa

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
M05BC02 Eptotermin alfa M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BC Bone morphogenetic proteins
Discover more medicines within M05BC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1398742, 1484423
Country: LT Valstybinฤ— vaistลณ kontrolฤ—s tarnyba Identifier(s): 1036398, 1056555

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈